Abstract LB-113: MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability in<i>BRAF</i>,<i>NRAS</i>and<i>NF1-</i>mutant melanomas
Ophélia Maertens(American Institutes for Research), Karen Cichowski(Brigham and Women's Hospital), Caroline J. Guild(Brigham and Women's Hospital), Keith T. Flaherty(Cancer Research Center), Terence C. Wong(Children’s Institute), Stephen J. Elledge(Howard Hughes Medical Institute), Alessandra G. Gavin(Brigham and Women's Hospital), Elodie Hatchi(Harvard University), Christian Bowman-Colin(Harvard University), Levi A. Garraway(Broad Institute), Ryan Kuzmickas(Brigham and Women's Hospital), Shailja Pathania(Harvard University), Chloe E. Emerson(Brigham and Women's Hospital), Haley E. Manchester(Brigham and Women's Hospital)
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k